RVNC
Revance Therapeutics, Inc.
NASDAQ: RVNC · HEALTHCARE · BIOTECHNOLOGY
$3.65
+0.00% today
Updated 2026-04-30
Market cap
$381.02M
P/E ratio
—
P/S ratio
1.48x
EPS (TTM)
$-3.34
Dividend yield
—
52W range
$0 – $0
Volume
4.1M
Revance Therapeutics, Inc. (RVNC) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-28.41M | $-38.91M | $-47.76M | $-55.07M | $-55.67M | $-59.83M | $-95.34M | $-104.25M | $-106.16M | $-178.50M | $-221.54M | $-193.55M | $-216.57M |
| Capital expenditures | $150000.00 | $319000.00 | $6.48M | $6.97M | $3.33M | $3.47M | $2.63M | $7.09M | $3.24M | $4.22M | $18.07M | $23.01M | $6.89M |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | $273000.00 | $79000.00 | $548000.00 | $6.53M | $12.39M | $11.95M | $13.23M | $16.27M | $17.92M | $36.45M | $43.43M | $52.34M | $47.81M |
| Free cash flow | $-28.56M | $-39.23M | $-54.23M | $-62.05M | $-59.00M | $-63.30M | $-97.97M | $-111.34M | $-109.40M | $-182.72M | $-239.61M | $-216.56M | $-223.46M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 | — | — | $269.87M | — | $6.50M | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | $167.12M | $30.58M | $-137.97M | $219.39M | $-209.49M | $97.90M | $165.11M | $-221.33M | — | — |